Kisunla (Donanemab-Azbt) for Alzheimer's

Overview
Kisunla is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease. This treatment is used for people with mild cognitive impairment or mild dementia stage of the disease. Kisunla is also known by its drug name, donanemab-azbt.

Kisunla is a biologic drug, specifically an amyloid beta-directed antibody. It works by targeting and helping to clear amyloid plaques (abnormal protein deposits) in the brain, which are believed to contribute to the symptoms and progression of Alzheimer's disease.

How do I take it?
Prescribing information states that Kisunla is administered as an intravenous infusion. The recommended dosage schedule is approximately 30 minutes every four weeks for the first three doses, followed by higher dosage every four weeks. The timing and size of doses can vary from person to person.

Side effects
Common side effects of Kisunla include amyloid-related imaging abnormalities (ARIA, changes in brain tissues), microhemorrhage (small brain bleeds), superficial siderosis (iron deposits in the brain tissue), and headaches.

Rare but serious side effects may include serious intracerebral hemorrhages (bleeding in the brain larger than 1 centimeter), symptomatic ARIA, focal neurologic deficits (problems with function of nerves, spinal cord, or brain) that can mimic ischemic stroke, and infusion-related reactions.

For more information about this treatment, visit:

Kisunla (Donanemab-Azbt) Injection, for Intravenous Use — U.S. Food and Drug Administration

Kisunla — Drugs.com